Latest Financial Results
Q1 2022
Quarterly Results
Sign Up for Email AlertsSign Up Today
Investor Relations
Analyst Coverage
A.G.P. / Alliance Global PartnersJames Molloy
Maxim GroupJason McCarthy, Ph.D
Overview
Synthetic Biologics, Inc. is a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need. The Company’s lead candidates are: (1) SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent (a) microbiome damage, (b) Clostridioides difficile infection (CDI), (c) overgrowth of pathogenic organisms, (d) the emergence of antimicrobial resistance (AMR) and (e) acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients, and (2) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.
View ProfileLeadership
Our experienced management team holds an extensive clinical and commercial track record.
Investor Relations
Synthetic Biologics, Inc.
Investor Relations Department
T: (301) 417-4364
info@syntheticbiologics.com
Transfer Agent
Corporate Stock Transfer, Inc.
3200 Cherry Creek Drive South
#430
Denver, CO 80209
T: (303) 282-4800